Alzheimer's Disease Demonstration Grants to States (ADDGS) Program

The summary for the Alzheimer's Disease Demonstration Grants to States (ADDGS) Program grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the Administration on Aging, which is the U.S. government agency offering this grant.

Alzheimer's Disease Demonstration Grants to States (ADDGS) Program: The statutory authority for grant awards for the Alzheimer's Disease Demonstration Grants to States program is contained in Sec. 398 of the Public Health Service Act (P.L. 78-410; 42 U.S.C. 280c-3). It was amended by the Home Health Care and Alzheimer's Disease Amendments of 1990 (PL 101-557) and by the Health Professions Education Partnerships Act of 1998 (PL 105-392). Section 398 of the Public Health Service Act (42 U.S.C. 398 et seq.), as amended, requires that grantees provide a 25% match (cash or in-kind). Waivers to this match requirement are not allowed. AoA plans to fund approximately six (6) to eight (8) new cooperative agreements nationwide through this competition. The cooperative agreements will be funded at a federal share of up to $400,000, with most awardees expected to receive $250,000 for a project period of eighteen months (contingent on the availability of funds.) If the applicant requests more than $250,000, up to the maximum award amount of $400,000, the proposal must clearly detail the reason(s) for requesting funds above $250,000 (i.e., the research project to be implemented does not have the necessary tools, such as training manuals, to facilitate project start-up; the potential number of people affected and the degree of enduring change in the state's system of long term care for people with ADRD or their caregivers; and/or the measurement tools required to ensure the fidelity of the proposed project are substantial.) A total of $1,700,000 has been allocated for these cooperative agreements. Projects carried out using ADDGS grant funds focus on: 1) Coordinating the development and operation with public and private organizations of diagnostic, treatment, care services provided within the State to individuals with Alzheimer's disease and related dementias and to the families and care providers of such individuals; 2) Providing ADDGS-statutorily defined direct services, which include, and are limited to, home health care, personal care, day care, companion services, short-term care in health facilities, and other respite care to individuals with Alzheimer's disease and related dementias who are living in single family homes or congregate settings. At least 50% of the total federal grant funds are to be spent on providing these direct services and no more than 10% of the total project funds can be spent on administrative costs; 3) Improving the access of such individuals to home-based or community-based long-term care services, particularly such individuals who are members of racial or ethnic minority groups, who have limited proficiency in speaking the English language, or who live in rural areas; and 4) Providing to health care providers, to individuals with Alzheimer's disease and related dementias, to the families of such individuals, to organizations established for such individuals and such families, and to the general public, information with respect to: (A) diagnostic services, treatment services, and related services available to such individuals and to the families of such individuals; (B) sources of assistance in obtaining such services, including assistance under entitlement programs; and (C) the legal rights of such individuals and such families. Alzheimer's disease (AD) is a progressive, degenerative disease of the brain, and the most common form of dementia. Discovered and described in 1906 by Dr. Alois Alzheimer, AD now affects approximately 5 million Americans. Unless a cure or prevention is found, it is estimated that the number of Americans with Alzheimer's will climb to 14 million by the middle of the next century. Although AD is not a normal part of aging, one in 10 persons over 65 and nearly half of those over 85 may have Alzheimer's disease. A small percentage of people in their 30s and 40s also develop the disease. Although AD eventually results in death, the disease can progress for years. A person with AD lives an average of 8 years, but can live as many as 20 years or more from the onset of symptoms. To focus attention on this need, to encourage states to develop models of assistance for persons with Alzheimer's disease and related dementias (ADRD), and to encourage close coordination and incorporation of those services into the broader home and community based care system, Congress funded the Alzheimer's Disease Demonstration Grants to States (ADDGS) program in 1991. Congress transferred the administration of the program to the AoA in 1998, in an effort to ensure coordination with other programs for older Americans. To date, the ADDGS program has proven successful in targeting service and system development to traditionally underserved populations, including ethnic minorities, low-income and rural families coping with Alzheimer's disease.